Results of Elamipretide Offer Additional Understanding on Primary Mitochondrial Myopathy Despite Failure to Meet End Points.

Published Date: 22 Jun 2023

Elamipretide failed to achieve its primary end points in one of the first phase 3 trials for primary mitochondrial myopathy, but a subgroup of patients with nuclear DNA defects showed improvement in the 6-minute walk test, raising additional concerns.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot